These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 33879671)

  • 21. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer.
    Iglesia MD; Vincent BG; Parker JS; Hoadley KA; Carey LA; Perou CM; Serody JS
    Clin Cancer Res; 2014 Jul; 20(14):3818-29. PubMed ID: 24916698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of differentially expressed genes between triple and non-triple-negative breast cancer using bioinformatics analysis.
    Zhai Q; Li H; Sun L; Yuan Y; Wang X
    Breast Cancer; 2019 Nov; 26(6):784-791. PubMed ID: 31197620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of microRNA-9 and microRNA-155 expression in triple-negative breast cancer.
    Jang MH; Kim HJ; Gwak JM; Chung YR; Park SY
    Hum Pathol; 2017 Oct; 68():69-78. PubMed ID: 28882698
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An eight-lncRNA signature predicts survival of breast cancer patients: a comprehensive study based on weighted gene co-expression network analysis and competing endogenous RNA network.
    Sun M; Wu D; Zhou K; Li H; Gong X; Wei Q; Du M; Lei P; Zha J; Zhu H; Gu X; Huang D
    Breast Cancer Res Treat; 2019 May; 175(1):59-75. PubMed ID: 30715658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delving into the Heterogeneity of Different Breast Cancer Subtypes and the Prognostic Models Utilizing scRNA-Seq and Bulk RNA-Seq.
    Xu J; Qin S; Yi Y; Gao H; Liu X; Ma F; Guan M
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioinformatics analysis of prognostic significance of COL10A1 in breast cancer.
    Zhang M; Chen H; Wang M; Bai F; Wu K
    Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32043519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-cell analysis reveals metastatic cell heterogeneity in clear cell renal cell carcinoma.
    Liu K; Gao R; Wu H; Wang Z; Han G
    J Cell Mol Med; 2021 May; 25(9):4260-4274. PubMed ID: 33759378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High CD90 (THY-1) expression positively correlates with cell transformation and worse prognosis in basal-like breast cancer tumors.
    Lobba ARM; Carreira ACO; Cerqueira OLD; Fujita A; DeOcesano-Pereira C; Osorio CAB; Soares FA; Rameshwar P; Sogayar MC
    PLoS One; 2018; 13(6):e0199254. PubMed ID: 29949609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening of DNA Damage Repair Genes Involved in the Prognosis of Triple-Negative Breast Cancer Patients Based on Bioinformatics.
    Wang N; Gu Y; Chi J; Liu X; Xiong Y; Zhong C; Wang F; Wang X; Li L
    Front Genet; 2021; 12():721873. PubMed ID: 34408776
    [No Abstract]   [Full Text] [Related]  

  • 30. Mesothelin expression is associated with poor outcomes in breast cancer.
    Li YR; Xian RR; Ziober A; Conejo-Garcia J; Perales-Puchalt A; June CH; Zhang PJ; Tchou J
    Breast Cancer Res Treat; 2014 Oct; 147(3):675-84. PubMed ID: 25193277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD2 Is a Novel Immune-Related Prognostic Biomarker of Invasive Breast Carcinoma That Modulates the Tumor Microenvironment.
    Chen Y; Meng Z; Zhang L; Liu F
    Front Immunol; 2021; 12():664845. PubMed ID: 33968066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SPOCK1 Is a Novel Transforming Growth Factor-β-Induced Myoepithelial Marker That Enhances Invasion and Correlates with Poor Prognosis in Breast Cancer.
    Fan LC; Jeng YM; Lu YT; Lien HC
    PLoS One; 2016; 11(9):e0162933. PubMed ID: 27626636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integration of whole-genome sequencing and functional screening identifies a prognostic signature for lung metastasis in triple-negative breast cancer.
    Xie G; Yang H; Ma D; Sun Y; Chen H; Hu X; Jiang YZ; Shao ZM
    Int J Cancer; 2019 Nov; 145(10):2850-2860. PubMed ID: 30977117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of a DNA Methylation-Based Prognostic Signature for Patients with Triple-Negative Breast Cancer.
    Gao Y; Wang X; Li S; Zhang Z; Li X; Lin F
    Med Sci Monit; 2021 May; 27():e930025. PubMed ID: 34003815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer.
    Cai J; Tian AX; Wang QS; Kong PZ; Du X; Li XQ; Feng YM
    Cancer Lett; 2015 Oct; 367(2):129-37. PubMed ID: 26210254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.
    Blok EJ; van den Bulk J; Dekker-Ensink NG; Derr R; Kanters C; Bastiaannet E; Kroep JR; van de Velde CJ; Kuppen PJ
    Oncotarget; 2017 Feb; 8(9):15610-15620. PubMed ID: 28121628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer.
    Sui S; An X; Xu C; Li Z; Hua Y; Huang G; Sui S; Long Q; Sui Y; Xiong Y; Ntim M; Guo W; Chen M; Deng W; Xiao X; Li M
    Theranostics; 2020; 10(26):11938-11949. PubMed ID: 33204321
    [No Abstract]   [Full Text] [Related]  

  • 38. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
    Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
    Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a 15-pseudogene based prognostic signature for predicting survival and antitumor immune response in breast cancer.
    Tan L; He X; Shen G
    Aging (Albany NY); 2020 Dec; 13(10):14499-14521. PubMed ID: 33378744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In silico recognition of a prognostic signature in basal-like breast cancer patients.
    Conte F; Sibilio P; Grimaldi AM; Salvatore M; Paci P; Incoronato M
    PLoS One; 2022; 17(2):e0264024. PubMed ID: 35167614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.